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BACKGROUND: Expediting cancer diagnosis may be achieved by targeted decreases in referral thresholds to increase numbers of
patients referred for urgent investigation.
METHODS: Clinical Practice Research Datalink data from England for 150,921 adults aged ≥40 were used to identify participants
with features of possible cancer equating to risk thresholds ≥1%, ≥2% or ≥3% for breast, lung, colorectal, oesophago-gastric,
pancreatic, renal, bladder, prostatic, ovarian, endometrial and laryngeal cancers.
RESULTS: The mean age of participants was 60 (SD 13) years, with 73,643 males (49%). In 2016, 8576 consultation records
contained coded features having a positive predictive value (PPV) of ≥3% for any of the 11 cancers. This equates to a rate of 5682/
100,000 patients compared with 4601/100,000 Suspected Cancer NHS referrals for these cancers from April 2016–March 2017. Nine
thousands two hundred ninety-one patient-consultation records had coded features equating to a ≥2% PPV, 8% more than met
PPV ≥ 3%. Similarly, 19,517 had features with a PPV ≥ 1%, 136% higher than for PPV ≥ 3%.
CONCLUSIONS: This study estimated the number of primary-care patients presenting at lower thresholds of cancer risk. The
resource implications of liberalising this threshold to 2% are modest and manageable. The details across individual cancer sites
should assist planning of English cancer services.
British Journal of Cancer; https://doi.org/10.1038/s41416-021-01541-4
INTRODUCTION
Prompt diagnosis of symptomatic cancer is a priority for patients,
the public and governments worldwide. This is particularly so in
the UK, which has worse survival from cancer than most
comparator countries [1, 2]. In the UK, most patients with
symptoms of possible cancer report initially to primary care. In
England, selection of patients for specialist investigations for
possible cancer is supported by recommendations in the 2015
‘Suspected cancer: recognition and referral,’ NG12 guideline
published by National Institute for Health Care Excellence [3].
This guidance describes presenting features (symptoms, signs and
abnormal blood test results) warranting investigation. It estab-
lished the principle of selecting patients for cancer investigation
based on the estimated cancer risk, and chose a threshold of 3%
risk warranting urgent investigation. This value was chosen, as a
balance between the benefit of liberalised investigation (com-
pared with the previous value of ~5%) and the potential harms of
overwhelming clinical services, or over-investigation [3]. Further-
more, for colorectal, lung and ovarian cancers, NG12 supports
testing overseen within primary care at levels below 3%, using
faecal immunochemical testing (FIT), chest X-ray and Cancer
Antigen 125 (Ca125), respectively. Times to diagnosis of patients
with the lower-risk presenting features of colorectal cancer have
reduced since NG12 was introduced [4].
Efforts continue to improve England’s cancer outcomes, with an
explicit target of 75% of new cancers to be diagnosed at stage I or
II (i.e. probably curable) by 2028, from the current level of around
54% [2]. One possible intervention to facilitate this would be to
lower the threshold risk for urgent investigation to 2%, or even
1%, for all cancers, which could expedite the diagnosis for some
patients. Such a change would place further demand for
investigations, on top of a considerable recent increase [5].
Demand for lower gastrointestinal endoscopy for all indications
doubled from 2012 to 2017 [6]. Imaging figures are similar [7].
Furthermore, there has been unprecedented strain on services
during the COVID-19 pandemic, which severely curtailed diag-
nostic services [8]. Cancer diagnosis is also costly: over £1bn is
spent annually in the UK on it [9]. Therefore, any change to the
threshold risk for cancer investigations requires estimates of the
potential increased demand.
In this study, we estimated how many patients in primary care
in England would be eligible for urgent cancer investigations
either overseen in primary care or performed in secondary care at
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a current risk threshold of ≥3%. We extended this to provide
estimates for putative ≥1% and ≥2% risk thresholds.
METHODS
Study design and setting
This was an observational cross-sectional study set in primary care using
data from the UK’s Clinical Practice Research Datalink (CPRD GOLD). The
study period was 1 January 2015 to 31 December 2016, to allow full
capture of participants meeting criteria in 2016. We studied participants’
records for the symptoms, signs and abnormal test results (collectively
termed “features” hereafter) for the eleven most common internal cancers:
bladder, breast, colon or rectum, endometrium, kidney, larynx, lung,
oesophago-gastric, ovary, pancreas and prostate. External cancers that are
associated with easily visible signs on clinical examination, such as skin
cancers, and haematological cancers, commonly diagnosed through blood
tests, were not studied.
Sample selection criteria
A random sample of 200,000 CPRD participants was supplied by the CPRD,
using the following inclusion criteria: aged 40 or over; continuous
registration at a CPRD general practice for at least 1 year before 1 January
2016; and complete CPRD records of up-to-date standard throughout the
study period. Only participants registered at practices in England were
included in our analyses, as there are different diagnostic pathways and
guidance across the devolved nations. This left a final study population of
150,921.
Variables
Participant characteristics. We calculated age from the year of birth.
Month and day of birth are not available with CPRD data (to protect
anonymity) so we assigned a birthday of 1 July. Smoking status adopted
the NG12 categories of “never-smoker” and “ever-smoker”.
Identification of features. We derived a list of features of cancer from the
systematic reviews published in NG12 for each of the cancer sites
(Appendix A). For laryngeal cancer, no primary-care evidence was available
when NG12 was being drawn up so features representing ≥1% risk of this
cancer were identified from a subsequently published study [10].
We assembled CPRD code lists representing each chosen feature, mostly
from a previous study [4], supplemented by a small number of new ones,
all created using robust methods [11]. These code lists are available in
Appendix B.
We searched each participant’s medical records using the code lists, and
participant-level variables were created for the presence/absence of each
feature. In line with usual practice, we interpreted the absence of a code
for a feature as an absence of the feature itself [12].
For abnormal blood test results, we compared a participant’s result with
the local laboratory’s reference range. The exceptions to this were tests for
anaemia, prostate-specific antigen (PSA) and CA125. For PSA, age-specific
values were used: ≥3.0 ng/ml for participants aged 50–69 years and 4.0 ng/
ml for ≥70 years [13]. To define anaemia, we used haemoglobin level <130
g/L in men and <120 g/L in women [14]. The threshold for CA125 was 35
U/L, as per NG12.
Identification of participants who meet criteria in NG12. We matched each
participant’s features with the criteria for urgent investigation in NG12 by
cancer site (Appendix A). Appendix A also describes the relevant study or
meta-analysis underpinning the selection of features, and identifies the
positive predictive value (PPV) of each feature (or combination thereof) for
each cancer and the population to which it should apply.
For criteria using paired or recurrent features, we required the second
feature to occur within one year of the first, following the methodology in
the literature underpinning many of the risk estimates [15].
Within cancer sites, participants were assigned an index date; namely,
the date of the earliest time they met any criterion for that site between 1
January 2016 and 31 December 2016. For paired or recurrent features, the
index date was the later of the two dates. Participants could have an index
date for more than one cancer site.
Assignment to risk bands. Within cancer sites, participants were assigned
to a risk band (1.0–1.9%, 2.0–2.9%, ≥3%) according to the PPV on the index
date. Participants with “Suspected-cancer” codes, but without a coded
specific feature, were assumed to meet criteria for urgent investigation
under the current NG12 guideline and were added to the ≥3% group.
Participants were not assigned to a risk band for any cancers with which
they had been diagnosed prior to 1 January 2016. For colorectal, lung and
ovarian cancers, triage testing exists within primary care. Test positivity
rates in the primary-care setting are estimated as: 15.9% (FIT) [16], 6%
(chest X-ray), [Bradley, BJGP, in press] and CA125 (6.8%), respectively [17].
For all three tests, a positive result carries a risk of ≥3% plus a
recommendation of specialist referral, so the appropriate percentage
was assigned to the ≥3% group.
Within cancer sites, numbers qualifying at each risk band represent
numbers of unique participants. The totals across cancer sites comprise
multiple contributions from individual participants.
Analysis
Simple descriptive statistics were used to report the cumulative numbers
of participants meeting criteria at the ≥1%, ≥2% and ≥3% risk thresholds
within cancer sites. The numbers of participants meeting criteria at each
threshold were then converted to a rate per 100,000 and reported with
95% confidence intervals. We estimated the rate (per 100,000 of the
population) in England eligible for urgent cancer investigation using totals
across all cancer sites for each risk band. These estimates are based on
Office for National Statistics data on the English population aged over 40
(27.5 million in 2016; 13.2 million males, and 14.3 million females) [18]. The
numbers of actual numbers of 2-week-wait appointments in England for
2016 are reported for comparison [19].
Study size
There were 1.88 million urgent suspected-cancer appointments in April
2016–March 2017, representing 6.8% of the English population of 27.5
million aged over 40 [18, 20]. A sample of 150,000 gives a margin of error
of 0.2 percentage points around an estimate of 6.8%.
Patient and public involvement
A member of the Patient and Public Involvement (PPI) group affiliated with
the Policy Research Unit (PRU) gave feedback on the lay summary of ISAC
ethics protocol application to the CPRD for this project and is a co-author
on this manuscript. The PRU’s PPI group comprises lay members with an
interest as public, patients and/or carers of those with cancer or suspected
cancer, and brings the public perspective to our research.
RESULTS
Participants
Our sample consisted of 150,921 participants registered at a
general practice in England. Participant characteristics are
described in Table 1. Comparison to Office for National Statistics
UK population data from mid-2016 showed that the sample
received was representative in terms of age and sex of the UK
population [18].
Participants meeting specific cancer risk thresholds
The features of cancer are included in Appendix A. These are listed
by cancer site, identifying criteria for urgent investigation, the
positive predictive value (PPV) of each feature (or combination
thereof) for that cancer and the population to which they should
apply. Appendix A also cites the relevant study or meta-analysis
underpinning the selection.
Table 1. Participant demographics.
Number of participants
Number (%)
Age in mid-2016 (years)
Mean (SD)
Male 73,643 (48.8) 59.8 (13.6)
Female 77,278 (51.2) 61.5 (14.4)
Total 150,921 (100.0) 60.7 (13.9)
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Outcomes
Numbers qualifying for urgent investigation. The cumulative
numbers of participants with features of cancer at each threshold
of increasing risk are reported as absolute numbers and per
100,000, by cancer site (Table 2). For the three cancer sites
(colorectal, lung and ovary) where urgent investigation in primary
care is available at the lower threshold of ≥1%, an additional
column (under the heading ‘Additional number qualifying for PC
testing’) shows the number of participants who would meet these
lower threshold criteria. The estimated number of those qualifying
for Primary Care testing who would have had a positive test result
is shown under ‘Estimated number positive results’. This is added
to the numbers meeting the higher-risk criteria of ≥2% or ≥3% to
give an adjusted number in our sample and an adjusted number/
100,000 population meeting criteria for referral. The percentage
change compared to the reference category of PPV ≥ 3% (the
current English threshold for urgent investigation) is reported for
thresholds ≥2% and ≥1%.
Comparison of estimates of participants eligible for urgent
investigation to the actual numbers of patients referred urgently
to secondary care in 2016–2017 in England showed a ratio of 1.2
between study estimates and actual numbers of appointments
across the cancer sites for which NHS data were reported.
DISCUSSION
Key results
This study estimated that people consulted English primary care
with features representing a ≥3% risk for one of the 11
commonest cancers at a rate of 5682 (95% CI 5566–5800) per
100,000 adults aged ≥40 in 2016. Liberalisation of criteria for
referral from a PPV of ≥3% to ≥2% across the 11 cancer sites
would lead to 6156 (95%CI 6035–6279) patients per 100,000
meeting criteria, an 8% increase compared to PPV ≥ 3%. Further
reduction to a threshold PPV of ≥1% would have increased
numbers eligible for urgent investigation to 12,932 (95% CI
12,763–13,102) patients per 100,000, a 136% increase compared
to PPV ≥ 3%.
Strengths and limitations
This study used CPRD data, which is considered representative of
primary care in England, the target population for application of
NG12 [12, 21]. Furthermore, our code lists to identify the features
of possible cancer were comprehensive and developed by robust
published methods: most had been used before [4, 11]. However,
there are limitations to CPRD data. Some symptoms of possible
cancer will not have been recorded, or were recorded in the ‘free
text’ area of the notes, which is unavailable to researchers for fear
of compromising anonymity. This missing data will have reduced
power, although we had sufficient power to give narrow
confidence intervals for our primary analyses. Missing data may
also have introduced misclassification bias for symptoms. Analysis
of coded data alone underestimates the true number of
participants with a symptom, by up to 30% for non-site-specific
symptoms such as abdominal pain, and by 20% for symptoms that
that are specific and highly predictive of a particular cancer [22].
Thus our estimates of criteria based solely on symptoms,
particularly for the 2% and 1% thresholds, are likely to be
moderate underestimates. In contrast, test results are automati-
cally coded into the CPRD record, effectively eliminating missing
data for that aspect.
We did not attempt to quantify any possible benefits from a
liberalisation of the threshold for specialist investigation. The
relationship between timeliness of symptomatic cancer diagnosis
and improvements in survival has not been studied empirically,
although a higher cancer referral rate has been associated with
reduced cancer mortality [23]. This relationship is complicated by
there being at least three mechanisms whereby survival could be
improved: a stage shift, a within-stage shift or an avoidance of
complications precipitating emergency admission. One modelling
study of the COVID-19-related diagnostic delays estimated a
2-month delay on breast, colorectal and bladder cancers to lead to
a reduction in 1-year net survival of 1.4–5.0%, 6.6–10.7% and
9.1–11.6%, respectively, where the ranges represent different age
bands from 40 years upwards [8]. If harms from delayed diagnoses
were of a similar magnitude to benefits from expedited diagnosis,
then an improvement of even 1 week in timeliness of diagnosis
could yield a survival benefit, perhaps as much as 1%. Such
improvements in timeliness of diagnosis of symptomatic cancer
are achievable, as seen following the introduction of NG12 in 2015
[4]. The benefit would not just be experienced by the modest
percentage of cancer patients whose sole presenting features
were in the 2.0–2.9% range, but also by those who presented with
low-risk features before developing higher-risk features. However,
we would caution against assuming that an 8% increase in
resource use would yield an 8% increase in—for example—
improved stage at diagnosis. It may do so—but it may not.
The disparity between the rate of patients eligible for specialist
cancer investigation and the rate of actual appointments offered
in 2016 was 20%. This is no surprise: it has long been recognised
that GPs do not slavishly adhere to guidance, including NG12.
Indeed, NG12 explicitly condones this, supporting GPs in making a
holistic assessment of the patient’s risk—ideally coming to a
shared decision about the need for investigation.
Use of the results—implications for policy and practice
There are powerful policy implications from this study, particularly
relating to any liberalisation of criteria for urgent investigation.
Based on our 11 cancers, it appears that a liberalisation to a 2%
threshold would have a modest impact on investigative resource
use, of around 8%. This increase in resources would not occur
evenly across all specialities: in percentage terms, patients with
possible pancreatic or laryngeal cancer would see the largest
increase.
For colorectal, lung and ovarian cancers, any increase in
demand for specialist diagnostic services should be mitigated by
primary-care testing. This principle is already present in NG12—
explicitly supporting investigation of possible cancer in primary
care for risks below 3% where a good primary-care test is available
[3]. We incorporated such testing in our methods. However,
primary-care testing is not available for all cancers. For upper
gastrointestinal cancers there is no current primary-care test that
can triage patients with low-risk features, so the additional
investigative burden would fall on endoscopy services, already
under considerable strain [24]. The resource implications of
lowering the investigation threshold to 1% are much larger. In
particular, eligibility for possible gastrointestinal cancer testing
would increase over 30 fold.
Lowering the threshold also has other implications beyond the
scope of this study, in terms of opportunity costs, and potentially
increasing patient anxiety and unnecessary investigation.
CONCLUSIONS
These results provide estimates of the impact of changing referral
thresholds for suspected cancer on numbers of patients referred
across 11 different cancer sites, which can be used to inform
future NHS policy in England. The detail of this study across
individual cancer sites and criteria will help future planning of
cancer services.
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